March 21, 2019, New York – Ludwig Cancer Research released today the full breadth of findings to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Ga., March 29 – April 3, 2019. Research conducted by more than 75 Ludwig scientists will be shared in plenary sessions, major symposiums, education sessions, poster sessions and more.
“The AACR Annual Meeting brings together the cancer community from across geographies, fields and sectors to share the latest advances in basic, translational and clinical research,” said Chi Van Dang, scientific director of the Ludwig Institute for Cancer Research and Editor-in-Chief of AACR’s Cancer Research journal. Dang, also a professor at the Wistar Institute, will present on circadian rhythms and cancer at a major symposium. “Year after year, Ludwig researchers take advantage of this highly anticipated scientific gathering to discuss cancer research breakthroughs, network with other experts and explore new collaborations.”
Ludwig scientists and affiliated researchers will present findings that span different cancer types and research areas. In the opening plenary, Ludwig Stanford’s Crystal Mackall will discuss next-generation CAR T cells designed to overcome tumor resistance.
During the six-day meeting, Ludwig scientists will cover a range of topics including the tumor microenvironment, combinations of immunotherapies, advances in early detection, diagnostics and therapeutics, and precision cancer medicine. Their research will advance the scientific community’s understanding of a range of cancers, including breast cancer, colon cancer, glioblastoma, melanoma, ovarian cancer and prostate cancer. Poster sessions will also delve into imaging, biomarkers, drug resistance and new trends in DNA methylation, among other themes.
Click here for a comprehensive list of Ludwig scientists’ activities at the Meeting.
###
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit http://www.
For further information, please contact Rachel Reinhardt, [email protected] or +1-212-450-1582.
Media Contact
Rachel Reinhardt
[email protected]
